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We designed an unexplored approach to cancer therapy: mitogenic overstimulation to 
increase dependence on stress response pathways, plus stress-targeted inhibitors to 
selectively kill cancer cells. As a proof of principle, we show that exogenous FGF2 
enhanced replication and proteotoxic stresses in different cancer cell lines, rendering 




In malignant transformation, cellular stress response pathways are dynamically 
mobilized to counterbalance oncogenic activity, keeping cancer cells viable. 
Therapeutic disruption of this vulnerable homeostasis might change the outcome of 
many human cancers, particularly those for which no effective therapy is available. 
Here, we report the use of Fibroblast Growth Factor 2 (FGF2) to demonstrate that 
further mitogenic activation disrupts cellular homeostasis and strongly sensitizes 
cancer cells to stress-targeted therapeutic inhibitors. We show that FGF2 enhanced 
replication and proteotoxic stresses in a K-Ras-driven murine cancer cell model, and 
combinations of FGF2 and proteasome or DNA damage response-checkpoint 
inhibitors triggered cell death. CRISPR/Cas9-mediated K-Ras depletion suppressed 
the malignant phenotype and prevented these synergic toxicities in these murine cells. 
Moreover, in a panel of human Ewing’s sarcoma family tumor cells, sub-lethal 
concentrations of bortezomib (proteasome-inhibitor) or VE-821 (ATR-inhibitor) 
induced cell death when combined with FGF2. Sustained MAPK-ERK1/2 
overactivation induced by FGF2 appears to underlie these synthetic lethalities, as late 
pharmacological inhibition of this pathway restored cell homeostasis and prevented 
these described synergies. Our results highlight how mitotic signaling pathways 
frequently overridden in malignant transformation might be exploited to disrupt the 
robustness of cancer cells, ultimately sensitizing them to stress-targeted therapies. 
This approach provides a new therapeutic rationale for human cancers, with important 
implications for tumors still lacking effective treatment, and for those that frequently 
relapse after treatment with available therapies. 
  
1. INTRODUCTION 
Several cellular stress response pathways are frequently mobilized in malignant cells 
to cope with an aggressive and highly proliferative phenotype. Identification and 
targeting of cancer cells-specific vulnerabilities resulting from these stresses is a 
promising therapeutic approach; particularly for cancers in which the driver oncogene 
is not clinically druggable. For instance, gain-of-function mutations or overexpression 
of RAS family members (KRAS, HRAS, and NRAS) are among the most prevalent 
oncogenic lesions in human cancers (Prior et al., 2012); and high levels of Ras activity 
are necessary to maintain the transformed phenotype in some Ras-driven cancers 
(Singh et al., 2009). Similar oncogene addiction is also described for Ewing’s Sarcoma 
Family Tumors (ESFT), which are a group of childhood and adolescence poorly 
differentiated cancers, arising from bone and soft tissues (Biswas and Bakhshi, 2016). 
The (11;22) (q24;q12) chromosomal translocation encoding the fused transcription 
factor EWS-FLI-1 is present in approximately 85% of all Ewing’s Sarcoma Family 
Tumor specimens and is established as the driver oncogenic lesion in these tumors 
(Toomey et al., 2010). In common with Ras-driven tumors, Ewing’s sarcoma tumors 
display a poor prognosis at metastatic stage (cure rate of 20-40%) and the lack of 
clinically effective targeted therapies (Gaspar et al., 2015). Hence, selective targeting 
of stress-response pathways supporting Ras and EWS-FLI-1-driven tumorigenesis 
might be game-changing for the therapy of these aggressive malignancies. 
Enhanced DNA damage and replication stress are probably the best characterized 
and exploited stresses resulting from malignant transformation induced by Ras, EWS-
FLI-1 and other oncogenes (Hills & Diffley, 2014). Genotoxic agents such as ionizing 
radiation (IR), cisplatin and gemcitabine are widely used in cancer therapy aiming to 
push tumor DNA damage/replication stress over a lethal threshold (Swift & Golsteyn, 
2014). More recently, checkpoint inhibition was shown to increase the cell death 
induced by these genotoxic agents (Prevo et al., 2012). 
The enhanced proteotoxic stress frequently found in malignant cells is also a clinical 
target in cancer therapy. Proteasome inhibition resulting in lethal proteotoxic stress is 
a protagonist treatment for some hematological cancers (Csizmar et al., 2016).  
Combined induction of protein misfolding further enhanced proteotoxic stress, 
increasing the cytotoxicity of proteasome inhibition in vitro and in vivo (Neznanov et 
al., 2011). Drawbacks of these stress-targeted therapies include the high overall 
toxicity and acquired resistance of genotoxic agents and proteasome inhibitors like 
bortezomib, limiting the therapeutic window and efficacy of these approaches (Kalal 
et al., 2017; Cavaletti & Jakubowiak, 2010). Altogether, these observations point that 
overload of replication or proteotoxic stress, especially in combination with the 
respective sensitizing inhibition, might efficiently target cancer cells-specific 
vulnerabilities. Therefore, identification of effective combinations “Stress 
induction/sensitizing inhibition” targeting selectively malignant cells is paramount. 
In this regard, exogenous administration of the Fibroblast Growth Factor 2 (FGF2) 
might be a viable alternative to overload cellular stress pathways in cancer cells. FGF2 
is the seminal member of a large family of signaling factors of undisputed importance 
for neurogenesis, morphogenesis, wound healing and angiogenesis, among other 
functions (Armelin, 1973; Itoh & Ornitz, 2011). Despite the many different pro-tumor 
roles attributed to FGF2 signaling (reviewed by Turner & Grose, 2010), a set of articles 
unequivocally demonstrate that FGF2 can also induce cytostatic and cytotoxic 
responses in different cancer cells, both in vivo and in vitro (Wang et al., 1998; Sturla 
et al., 2000; Williamson et al., 2004; Fogarty et al., 2007). In this last context, we have 
also previously shown that FGF2 restrains the proliferation of murine malignant cells, 
in which wild-type Kras is highly amplified and overexpressed (Costa et al., 2008; 
Salotti et al., 2013). Because FGF2 is an activator of mitogenic signaling pathways, 
we hypothesized that the toxicity induced by this growth factor in cancer cells might 
also intensify the mobilization of stress pathways, further increasing their dependency 
on these pathways for cell viability. 
Here, we tested whether FGF2 can selectively sensitize cancer cells to stress targeted 
therapeutic inhibitors. We found that in K-Ras-driven mouse Y1 malignant cells FGF2 
stimulation disrupts proteostasis and enhances tonic replication stress and DNA 
damage response (DDR) activation. Concomitant proteasome or checkpoint inhibition 
induced cell death in a K-Ras-dependent manner. Importantly, in human ESFT cells, 
combined FGF2 signaling activation and sub-lethal doses of proteasome or checkpoint 
inhibitors also triggered cell death. Moreover, FGF2 induced sustained MAPK-ERK1/2 
overactivation in Y1 and ESFT cells; and K-Ras depletion or late pharmacological 
MAPK inhibition, respectively, prevented FGF2 sensitization to these stress-targeted 
inhibitors. These findings indicate that further activation of mitogenic signaling can be 
employed to overload stress response pathways selectively in cancer cells, disrupting 
their homeostatic robustness, and increasing the cytotoxicity of stress-targeted 
therapies. 
  
2- MATERIALS AND METHODS 
2.1- Cell lines, cell culture and treatments 
The Y1 murine adrenocortical carcinoma cell line was obtained from ATCC. Y1 cells 
were grown at 37 ºC in a 5% CO2 atmosphere in Dulbecco’s modified Eagle’s medium 
DMEM (Gibco) supplemented with 10% fetal bovine serum (FBS). The Y1D1 subline 
(Schwindt et al, 2003) was cultured in the same conditions as Y1, and the growth 
medium was supplemented with 0.1 mg/mL geneticin (G418; Invitrogen). Whenever 
G0/G1 synchronization by serum starvation was necessary DMEM-FBS medium was 
removed, plates were washed with PBS, and cells were grown in FBS-free DMEM for 
48h prior any stimulation. ESFT cells (A673, RD-ES, SK-N-MC and TC-32) were kindly 
given by Professor Susan Burchill. A673 and SK-N-MC cells were grown in DMEM 
10% FBS, TC-32 cells were grown in RPMI 1640 10% FBS and RD-ES cells were 
grown in RPMI 1640 15% FBS. Where indicated, cells were treated with recombinant 
human FGF2 protein (Abcam ab9596); Colchicine (Sigma C9754); the MEK inhibitor 
U0126 (Promega V1121); Bortezomib (#S1013); ATM inhibitor KU55933 (#S1092); 
ATR inhibitor VE-821 (#S8007); p38 inhibitor SB202190 (S1077) and MEK inhibitors 
Selumetinib (#S1008) and Trametinib (S2673); all these last inhibitors from 
Selleckchem. 
2.2- Cell cycle analysis 
For BrdU/Propidium Iodide cell cycle analyses, after the indicated treatments, cells 
were resuspended and fixed in ice-cold 75% ethanol in PBS overnight at 4 ºC. BrdU 
was added at 50 µM for 30 minutes before harvesting. Fixed cells were treated with 2 
M HCl and 0.5% Tween-20 for 15 min for DNA denaturation and then washed 
sequentially with 0.1 M sodium tetraborate (pH 9.5) and ice-cold PBS. Cells were 
incubated with Alexa Fluor® 488 anti-BrdU (Invitrogen B35130) and subsequently 
treated with 10 mg/mL RNase A and stained with 50 mg/mL propidium iodide in PBS 
for 20 minutes before analysis in the flow cytometer.  
For all flow cytometer experiments, data were acquired with Attune NxT flow cytometer 
(Life Technologies) and analyzed with FlowJo V.10 software (Treestar, INC.). At least 
20000 cells per sample were analyzed. 
2.3- Histones on cell cycle assays 
For phospho-histone H3 (S10) or phospho-H2AX-S139 (γ-H2AX) stains along cell 
cycle, after treatment cells were fixed as described above, washed in PBS and 
incubated for 1h with the conjugated histone antibodies (histone H3 S10 Millipore 06-
570-AF488 or γ-H2AX Thermo Fisher 53-9865-82) Samples were then treated with 10 
mg/ml RNase A and stained with 50 mg/ml propidium iodide in PBS for 20 minutes 
prior to analysis by flow cytometry. 
2.4- Protein per cell assay 
To measure protein/cell, 2,5x104 cells per 35 mm dish were plated, let to adhere 
overnight and then serum starved as described for synchronization. After 48h, cells 
were stimulated with FBS in presence or absence of FGF2 as indicated for each 
experiment. For each condition and time point we harvested three plates for counting 
cells, as described below for growth curves, and three plates for measuring total 
protein concentration. To estimate the amount of protein per cell we measured the 
amount of protein from each plate using Bradford method and divided by the number 
of cells counted from each plate of the same time point and condition. 
 
 2.5- Western blots 
Antibodies for Western blot Western blot were as follows: IRE1α (3294 Cell signaling), 
Bip (3183 Cell signaling), phospho-S6 Ser235/236 (4856 Cell Signaling), phospho-
eIF4E Ser209 (9741 Cell Signaling), α-Tubulin (sc-8035 Santa Cruz) phospho-H2AX 
S139 (ab11174 Abcam), ChK1 (ab47574 Abcam), phospho-ChK1 S345 (sc-17922 
Santa Cruz), phospho-ChK2 T383 (ab59408 Abcam), p38 (9212 Cell Signaling); 
phospho-p38 T180/Y182 (sc-15852-R Santa Cruz), p21 (sc-397 Santa Cruz), HPRT 
(sc-20975 Santa Cruz), K-Ras (sc-30 Santa Cruz), Actin (ab6276 Abcam), phospho-
ERK Thr202/204 (4370 and 9101 Cell Signaling) and ERK (4695 and 9102 Cell 
Signaling). Analysis was performed by standard methods using enhanced 
chemiluminescence or fluorescence. Images were obtained using Uvitec Alliance 9.7 
documentation system (Uvitec) or Odyssey system (Licor) according to the 
manufacturer’s settings. 
2.6- Cell death assay 
For AnnexinV/PI stain cells were plated on 35 mm dishes and treated as described for 
each experiment. Then, culture media were collected and reserved, plates were 
washed with 450 µl of PBS, which was also reserved on the respective tubes and cells 
were released with 150 µl of trypsin for up to 5 minutes. Cells were then suspended 
and homogenized with the respective culture medium/PBS. The volume of all the 
suspensions were adjusted to 2 ml. 250 ul of each cell suspension were mixed 1:1 
with 2x Annexin binding buffer (300 mM NaCl, 2 mM MgCl2, 10 mM KCl, 3,6 mM CaCl2, 
20 mM HEPES pH 7,4) containing 1:10000 AnnexinV-FITC (produced and kindly given 
by Dr. Shankar Varadarajan’s lab). After 10 minutes, 5 µl of PI 50 µg/ml were added 
to each tube and mixed by inversion. Fixed volumes of these cell suspensions were 
then analyzed using Attune NxT Flow cytometer (Thermo Fisher Scientific Invitrogen) 
allowing combined determination of cells viability and total amount of cells per plate 
whenever necessary. At least 20000 cells were analyzed for each individual sample.  
2.7- Detection of BrdU foci under native DNA conditions 
For detection of long fragments of single stranded DNA (ssDNA), characteristics of 
replication stress, exponentially growing cells in coverslips incorporated 
bromodeoxyuridine (BrdU) at 50 mM for 48 hours into DNA. After that, we washed the 
coverslips and added fresh DMEM medium with or without 10 ng/mL FGF2 for 24 
hours. To ensure that all cells incorporated BrdU, 1 additional coverslip for each 
condition analyzed were prepared to be subjected to DNA denaturation using 2 M HCl. 
Next, cells were fixed using 4% of paraformaldehyde in PBS and permeabilized with 
0.2% Triton-X 100. BrdU was detected (when accessible) using α-BrdU-rat (ab6326 
Abcam) followed by secondary antibody goat anti-rat conjugated to Alexa Fluor 488 
(A-11006 Thermo Scientific). Stained coverslips were mounted with VECTASHIELD® 
Mounting Medium with DAPI (Vector Labs). Images were captured using Olympus 
BX51 fluorescence microscope coupled with a digital camera (XM10, Olympus), and 
analyzed using Olympus Cell F software (version 5.1.2640). At least 65 cells were 
analyzed per coverslip. 
2.8- Cas9-mediated K-Ras depletion 
To deplete K-Ras expression in Y1 cells, we designed and tested five different specific 
gRNAs against the k-ras gene using CRISPR design tool (http://crispr.mit.edu/). A 
scramble sequence was also designed for control. Sequences are shown below (table 
1). 
 Table 1: gRNA sequences 
1. K-Ras 5’ CTCCCGCGCCATTTCGGACC 3’ 
2. K-Ras 5’ CCTGAGGCGCGGCGGCTCCG 3’ 
3. K-Ras 5’ AGATATTCACCATTATAGGT 3’ 
4. K-Ras 5’ AAGAGGAGTACAGTGCAATG 3’ 
5. K-Ras 5’ CTGAATTAGCTGTATCGTCA 3’ 
Scramble 5’ GCACTACCAGAGCTAACTCA 3’ 
  
Oligos were cloned into LentiGuide-Puro plasmid (a gift from Feng Zhang, Addgene 
plasmid # 52963) according to described by Sanjana and co-workers (Sanjana et al., 
2014). For lentivirus production, LentiGuide-Puro constructs, psPAX2 (a gift from 
Didier Trono, Addgene plasmid # 12260), pCMV-VSV-G (a gift from Robert Weinberg, 
Addgene plasmid # 8454) were transfected into HEK293T cells using lipofectamine 
3000 reagent according manufacturer’s protocol. 48h after transfection, viral 
supernatants were collected and filtered. Y1 cells were then co-transduced with the 
LentiCas9-Blast and the individual LentiGuide-Puro constructs in the presence of 8 
µg/ml of polybrene (Santa Cruz Biotechnology sc-134220). 48h after Y1 transduction, 
cells were selected with 3 µg/ml of puromycin and 7 µg/ml of blasticidin for 7 days 
before testing knock out efficiency. For all experiments here, we used the subline 4 
(hereafter Y1ΔK), which displayed the lower levels of K-Ras expression.  
2.9- Clonogenic and viability assays 
The indicated amounts of cells per well were plated on 6-wells or p60 plates (figure 4B 
only), let to adhere overnight and then treated as described. After that, the culture 
media were replaced every other day until the end point. Cells were then washed with 
PBS, fixed and stained in a fixing/staining solution (0.05% crystal violet, 1% 
formaldehyde, 1% methanol in PBS) and washed abundantly. Images were acquired 
using GelCount colony analyser (Oxford Optronics, Oxford, UK).  
2.10- Growth curves 
At day 0, 3x104 cells per 35 mm culture dish were plated in DMEM-FBS medium with 
or without FGF2. At the indicated days, cells were harvested in triplicates, fixed in 
formaldehyde 3.7%, diluted in Phosphate Buffered Solution (PBS) and stored. The 
medium of reminiscent plates was changed in every 2 days. Cells were later counted 
in a Z2 Beckman Coulter® counter. 
2.11- Non-adherent proliferation assay. 
At day 0, 1x104 cells per well were plated on ultra-low attachment 96 wells plates 
(Corning CLS3474). Relative cell viability/proliferation was measured after 1 day, to 
set up a baseline, and after 10 days using CellTiter 96 AQueous (Promega G3582) 
according to the manufacturer’s protocol. A least 9 wells per cell were assayed at each 
time point.  
2.12- Statistical analyses 
Bar graphs with two columns were analyzed with paired Student’s t-test and bar 
graphs with tree or more columns were analyzed by one-way ANOVA of variance 
followed by multiple comparison post-test. Growth curves were analyzed by two-way 
ANOVA of variance followed by multiple comparison post-test. All graphics and 
statistical analyses were performed using GraphPad Prism 7 software. 
  
3- RESULTS 
3.1- FGF2 impairs cell cycle progression in K-Ras-driven cancer cells 
We previously showed that FGF2 triggers G0/G1→S transition but irreversibly 
restrains the proliferation of K-Ras-driven Y1 malignant cells (Costa et al., 2008). Y1 
cells are poorly synchronized by serum starvation. Hence, to address FGF2 effects 
along cell cycle progression accurately, we initially used the Y1 D1 subline. These 
cells, which we described elsewhere (Schwindt et al., 2003), display strict control of 
quiescence/proliferation switch in response to serum, and are phenotypically identical 
to parental Y1 cells regarding karyotype, K-Ras overexpression and malignant 
phenotype. 
Initially, we followed cell cycle progression of G0/G1 arrested Y1D1 cells after serum 
stimulation +/- FGF2, collecting samples every 2h, with a 30 minutes pulse of BrdU 
uptake into DNA, immediately before cell harvesting (Figure 1A and 1B). Flow 
cytometry results showed that FGF2 delayed both cell entry in and progression 
through S phase (Figure 1B, upper and middle panel). In FGF2-treated samples, after 
20h of stimulation, we observed BrdU unlabeled S-phase cells, indicating DNA 
synthesis arrest (Figure 1A arrows). Moreover, between 24 and 48h, we found a 
parallel decrease in S-phase and accumulation in G2/M sub-population (Figure 1B, 
middle and lower panel). This accumulation likely was due to G2 arrest, since mitosis 
blockage by colchicine induced G2 and M-phase accumulation in serum-stimulated 
but not in FGF-2-treated cells between 24 and 36h (Figure 1C, top and middle panel). 
Notably, about 40% of the FGF2-stimulated cells remained in G0/G1 phase 
irrespective of colchicine addition (Figure 1B and 1C, bottom panel); indicating that 
many of the FGF2-stimulated cells were not even able to leave G1 phase. These 
results showed that FGF2 compromises cell fitness, impairing the progression 
throughout the cell cycle in these Ras-driven malignant cells.                                                                                                                                                                                                                                                                                                             
3.2- FGF2 exacerbates replication stress and sensitizes K-Ras-driven cancer 
cells to checkpoint inhibition toxicity 
The S-phase cells displaying DNA synthesis arrest in the flow cytometry data (Figure 
1A arrows) suggested that FGF2 induced replication stress in this K-Ras-driven cell 
model. As unresolved replication arrest generates double-strand breaks, we 
measured the levels of the DNA damage marker phospho-H2AX histone (γ-H2AX) 
(Gagou et al., 2010) in Y1 cells stimulated by serum +/- FGF2. Serum-stimulated cells 
exhibited moderate levels of γ-H2AX, and these levels increased over 3.5-fold by 
FGF2 stimulation (Figure 2A). As a more specific readout of replication stress, we 
incorporated the thymidine analogue BrdU to these cells and measured single-
stranded DNA (ssDNA) foci at native conditions. FGF2 stimulation resulted in about 
45% of the cells showing more than 10 ssDNA foci after 24h, comparing to less than 
3% of the control cells (Figure 2B and 2C). To further confirm that such DNA damage 
results from replication stress, we analyzed the distribution of γ-H2AX positive cells 
along the cell cycle at three different time points after stimulation. Corroborating the 
above results, serum-stimulated cells displayed moderate γ-H2AX staining, and FGF2 
increased γ-H2AX-positive cell population 18 and 24h after stimulation (Figure 2D). In 
all samples γ-H2AX-positive cells were almost exclusively found in S and G2 phases, 
pointing that the observed DNA damage in these cells is likely a consequence of 
replication stress. 
These observations prompted us to probe for the engagement of the DNA Damage 
Response (DDR). We reasoned that DDR and checkpoint activation might contribute 
to the observed cell cycle arrest triggered by FGF2 in these cells, as a protective 
response against FGF-induced replication stress. We first assessed the activation 
status of classical DDR and checkpoint effector proteins, i.e., Chk 1 and 2, p21 and 
p38 (Reviewed by Harper & Elledge, 2007). The results showed that FGF2 does not 
alter the levels of active Chk2; however, FGF2 increased the levels of phosphorylated 
Chk1, p38 and p21 comparing to serum-stimulated samples (Figure 2E). These results 
confirmed that FGF2-induced replication stress triggers DDR and checkpoint 
activation in these cells. 
Checkpoint inhibition prevents cell cycle arrest induced by DNA damaging 
chemotherapy, forcing cancer cells into a defective mitosis and consequent cell death 
(Huntoon et al., 2013). To assess whether combined FGF2 signaling and checkpoint 
inhibition could lead to this same outcome, we focused on ATM and ATR, the two 
major kinases controlling checkpoint response (Harper & Elledge, 2007). We treated 
cells with specific ATR (VE-821) (Reaper et al., 2011) and ATM (KU-55933) (Hickson 
et al., 2004) pharmacological inhibitors for 48h in the presence or absence of FGF2, 
and measured cell death on the flow cytometer. FGF2 only modestly increased cell 
death compared to serum-stimulated control samples. ATM inhibition had no 
significant effect on cell death with or without FGF2. ATR inhibition alone moderately 
increased cell death. Strikingly, the association of VE-821 and FGF2 induced over 
40% of cell death after 48h (Figure 2F and 2G).  
Altogether, these results indicate that Y1 cells, as proposed for other cancer models, 
deal with chronic replication stress and rely on checkpoint activation for cell survival. 
FGF2 signaling upregulated such basal replication stress leading to cell cycle arrest 
and, at the same time, increasing checkpoint dependence. Thus, FGF2 sensitizes this 
K-Ras-driven malignant model to cell death induced by ATR-mediated checkpoint 
inhibition. 
3.3- FGF2 induces proteotoxic stress and sensitizes K-Ras-driven cancer cells 
to bortezomib cytotoxicity  
In agreement with our previous report (Costa et al., 2008), flow cytometry data from 
FGF2-treated cells presented on figure 1 showed increased cell size (FSC) and 
internal complexity (SSC) comparing to serum-stimulated control cells (Figure 3A). To 
further investigate this dual effect of FGF2 blocking proliferation but keeping cells 
growing, we stimulated serum starved Y1 cells with serum +/- FGF2 and measured 
average size and the amount of protein per cell.  FGF2-stimulated cells displayed 
increased cell size and about twice the amount of protein/cell measured on serum-
stimulated samples after 48 and 72h (Figure 3B). These results indicated that although 
FGF2 triggered cell cycle arrest in Y1 cells, it stimulated cell growth concerning volume 
and mass.  
The rates of protein synthesis and degradation show physiological fluctuations; 
however, an optimal balance between these processes is required to warrant cell 
viability (Walter & Ron, 2011). We then investigated whether this protein overload 
induced by FGF2 results in proteotoxic stress and, consequently, Unfolded Protein 
Response (UPR) activation. To this end, we measured the levels of the endoplasmic 
reticulum kinase IRE1α and the molecular chaperone Bip, two core sensors of UPR, 
which are upregulated in cells facing proteotoxic stress (Ron & Walter, 2007). We 
found increased levels of both proteins at 48 and 72h-FGF2-stimulated cells, even in 
serum-free media, comparing to serum-stimulated control samples (Figure 3C, left). 
Interestingly, despite this active UPR, FGF2-stimulated cells displayed high levels of 
both, phosphorylated S6 ribosomal protein and eukaryotic translational initiation factor 
4E (eIF4E) (Figure 3C, right). The phosphorylated forms of these proteins indicate 
active protein synthesis (Sonenberg & Hinnebusch 2009); implying that FGF2 
aggravates the proteotoxic stress by maintaining active protein synthesis irrespective 
of an ongoing activated UPR.  
The enhanced proteotoxic stress of malignant cells is a clinical target in cancer therapy 
(Csizmar et al., 2016). Hence, we tested if, beyond the cytostatic effect as a single 
agent, FGF2 could sensitize Y1 cells to the cytotoxicity of proteasome inhibition. We 
treated the cells with FGF2 for 24h and then added bortezomib (BTZ) for additional 
72h before harvesting. We then measured cell death by annexin V/Propidium iodide 
double stain on the flow cytometer. In the absence of FGF2, Y1 cells were very tolerant 
to 20 nM of BTZ for 72h, showing almost 90% of live cells. In contrast, the combination 
of FGF2 and BTZ reduced the percentage of live cells to less than 70%, while FGF2 
alone had only minor effects on cell death (Figure 3D and 3E). These observations not 
only show that FGF2 stress response disrupts the proteostasis, but also that it can be 
combined with proteasome inhibition to trigger cell death in these K-Ras-driven cancer 
cells. 
3.4- K-Ras depletion prevents FGF2 toxicity and sensitization to checkpoint or 
proteasome inhibition in K-Ras-driven cancer cells 
The malignant phenotype of Y1 cells is attributed to the overexpression of the wild-
type K-Ras protein resulting in high basal levels of K-Ras-GTP (Schwab et al., 1983). 
Using the isoform unspecific RasN17 dominant negative, we previously proposed that 
FGF2 toxicity in Y1 cells depends on high basal levels of K-Ras-GTP (Costa et al., 
2008). To link causally the high levels of K-Ras protein to FGF2 toxicity and 
sensitization to stress-targeted inhibitors, we performed Cas9-mediated genome 
editing to deplete K-Ras protein in these cells. After antibiotic selection, the resultant 
polyclonal subline (hereafter Y1ΔK) displayed more than 10-fold reduction in K-Ras 
protein levels, comparing to the scramble-transduced control cells (hereafter Y1-scb) 
or the parental Y1 cells (Figure 4A). 
We next enquired whether K-Ras depletion impacted on viability and proliferation of 
Y1 cells, as well as its likely protective effect from FGF2 toxicity. Clonogenic assays 
showed no significant change in cell viability caused by K-Ras depletion (Figure 4B). 
Moreover, K-Ras depletion prevented FGF2 toxic effects on long-term viability of Y1 
ΔK cells (Figure 4B). Furthermore, growth curves indicated similar proliferation rates 
in Y1ΔK cells comparing to both, parental Y1 and Y1-scb control cells, and FGF2 did 
not impact on cell proliferation of this K-Ras depleted subline (Figure 4C). Conversely, 
K-Ras depletion restrained the proliferation of Y1 ΔK cells under non-adherent growth 
conditions (Figure 4D). This set of results shows that K-Ras depletion elicited robust 
survival and proliferation in solid substrate but suppressed some malignant phenotype 
traits in this cell model.  
We then investigated whether K-Ras depletion is sufficient to prevent the cell death 
induced by simultaneous FGF2 stimulation and proteasome or ATR-checkpoint 
inhibition in these cells. To this end, we treated Y1-scb and Y1 ΔK cells with 
combinations of FGF2, bortezomib and VE-821 in the same regimens described 
above, and measure cell death by flow cytometry. The results for Y1-scb cells, as 
expected, were similar to those shown for Y1 parental cells; with the combinations of 
FGF2 with VE-821 or bortezomib inducing about 40% and 30% of cell death, 
respectively (Figure 4E and 4F, left). On the other hand, in Y1ΔK cells, K-Ras depletion 
largely prevented the cell death induced by the combinations of FGF2 and VE-821 
(Figure 4E, right), or bortezomib (Figure 4F, left). To address the effects of these 
toxicities on long-term cell viability, we treated both cells using the same regimens 
described above, washed out FGF2 and the inhibitors and cultured the cells for 
additional 10 days.  In agreement with the flow cytometry results, combinations of 
FGF2 and VE-821 or bortezomib strongly reduced the long-term viability of Y1-scb 
cells (figure 4G, left); and K-Ras depletion fully prevented these toxicities in Y1ΔK cells 
(figure 4G right). Altogether, these data indicated that, in these cells, FGF2 toxicity 
and the sensitization to proteasome or ATR checkpoint inhibition depends on K-Ras 
overexpression and malignant phenotype.  
3.5- FGF2 triggers sustained MAPK-ERK1/2 overactivation and lethally 
sensitizes human cancer cells to proteasome and checkpoint inhibitors 
The above data, focused on K-Ras-driven murine Y1 cancer cells, implied that 
mitogenic signaling activation combined with stress-response pathways inhibitors 
could disrupt the homeostatic robustness of cancer cells resulting in cell death. Hence, 
we asked whether this hypothesis would hold true for human cancer cells. Cytostatic 
and cytotoxic effects of FGF2 over ESFT cells have been reported by different 
researchers in the last decades, with the specific molecular mechanisms of this toxicity 
varying among these studies (Schweigerer et al., 1987; Williamson et al., 2004; 
Passiatore et al., 2011).  Thus, we tested A673, RD-ES, SK-N-MC and TC-32 ESFT 
cells for the toxicities of these combinations of FGF2 and proteasome or checkpoint 
inhibitors. We focused on the potential of these regimens to kill cancer cells, 
irrespectively of the cell death subroutine engaged, as well as to reduce the number 
of viable cancer cells; using concentrations in which none of these stimuli induce 
pronounced cell death as a single agent. Thus, for each cell line, we plated the 
indicated number of cells and, after treatments, we measured cell death by annexin 
V/Propidium iodide double stain and the total number of cells in each sample by flow 
cytometry. For proteasome inhibition, we treated the cells with FGF2 for 24h and then 
added bortezomib for additional 48h before harvesting. The regimen for checkpoint 
inhibition was 72h treatment with FGF2 combined with ATM (KU-55933), ATR (VE-
821) or both inhibitors; since the functions of these kinases can overlap but are not 
redundant (Cimprich & Cortez, 2008). Overall, the combination of FGF2 and 
proteasome or checkpoint inhibition increased the cell death and reduced the number 
of live cells to a greater extent than the respective stimuli as single agents in all four 
cancer cell models (figure 5A). For proteasome inhibition, striking results were found 
in A673, SK-N-MC and TC-32 cells, in which the association with FGF2 reduced the 
number of live cells to about 1/3 of the observed for bortezomib alone (figure 5A). In 
all ESFT cells, the association of FGF2 and VE-821 reduced the number of live cells 
to about half of the measured using this ATR inhibitor as a single agent (figure 5A). 
While the association of FGF2 and KU-55933 resulted in significant increased toxicity 
only in A673 cells (figure 5A); in agreement with the role of ATR as the major player 
in the replication stress response (Saldivar et al, 2017).  
We next addressed the effects of proteasome or ATR-checkpoint inhibition on long-
term cell viability with or without FGF2. We treated A673, SK-N-MC and TC-32 cells 
as described above, washed out FGF2 and the inhibitors and cultured the cells for 
additional 10 days. The results show minor or no effects of FGF2, bortezomib or VE-
821 after these time for all three cells. Conversely, the associations of FGF2 with these 
inhibitors were even more toxic than anticipated by the flow cytometry data, resulting 
in a massive reduction in cell viability after 10 days (figure 5B). These data 
demonstrated that FGF2 signaling activation can also sensitize human cancer cells to 
proteasome or checkpoint therapeutic inhibitors. 
Ras, EWS-FLI-1 and many other driver oncogenes rely on aberrant MAPK-ERK 
signaling pathway activation to promote tumorigenesis (Silvany et al., 2000; Dhillon et 
al., 2007). Thus, we argued whether further overactivation of this same pathway might 
underlie FGF2 toxicity and the observed increased mobilization and dependence on 
stress pathways. Our results showed that FGF2 signaling sustains higher levels of p-
ERK1/2 even 24h after stimulation, comparing to control cells grown in complete 
media, in A673, TC-32, and Y1 cells. (figure 5C). This sustained MAPK-ERK activation 
correlates with the upregulation of UPR (IRE1α) and DDR (p-Chk1, p-p38, and p21) 
markers (figure 5C). Pharmacological inhibition of MEK1/2 using the potent and 
selective inhibitor selumetinib, even 8h after FGF2 stimulation, turned off sustained 
ERK activation and restored cell homeostasis (figure 5C). Coherently, K-Ras 
depletion, which we showed above to protect from FGF2 toxicity and sensitization to 
proteasome and checkpoint inhibition, also prevented sustained MAPK overactivation 
in Y1ΔK cells (figure 5D). Finally, we used the same regimens described for figure 5B 
and added the MEK1/2 inhibitor 8h after FGF2 stimulation. Disruption of FGF2-
induced sustained MAPK signaling alleviated or prevented the long-term toxicity 
triggered by the combinations of FGF2 and ATR-checkpoint or proteasome inhibition 
in A673, TC-32, and Y1 cells. (figure 5E).  
Because we formerly reported that MAPK inhibition with the MEK inhibitor U0126 
failed to prevent FGF2 toxicity in Y1 cells (Salotti et al., 2013), we next performed 
parallel western blots and viability assays using a third and highly potent MEK inhibitor, 
trametinib, to address these apparent discrepancies. The results showed that U0126 
poorly alleviates the sustained MAPK-ERK1/2 activation induced by FGF2 in Y1 and 
ESFT cells, comparing to selumetinib and trametinib (figure S1A). Moreover, 
corroborating the results using selumetinib (figure 5D), trametinib fully prevented the 
described toxicities in these cells, whereas U0126 provided partial or no protection 
(figure S1B, left). In addition, Williamson and co-workers proposed that p38 signaling 
underlies FGF2-toxicity in TC-32 ESFT cells (Williamson et al., 2004). We now 
enquired whether p38 inhibition would prevent the cell death induced by combinations 
of FGF2 and VE-821 or bortezomib in three ESFT cells (TC-32, A673, and SK-N-MC), 
and also in Y1 cells. The results showed that p38 inhibition prevents the synergic 
toxicity of FGF2 and VE-821, but not of FGF2 plus bortezomib in TC-32 cells. 
Moreover, in the other two ESFT cell models and the murine Y1 cells, p38 inhibition 
failed to prevent toxicity, in fact, it synergized with bortezomib to enhance toxicity in 
SK-N-MC cells (supplementary figure S1B, right). These results point that MAPK-
ERK1/2, but not p38 signaling underlies the described toxicities in these malignant 
cells.  Therefore, by sustaining MAPK-ERK1/2 overactivation, a signaling pathway 
frequently overridden in malignant transformation, FGF2 reinforces the dependence 
on stress response pathways, increasing the toxicity of stress-targeted therapeutic 
inhibitors in both murine and human cancer cells.  
  
4- DISCUSSION 
Identification and effective targeting of stresses inherent to the malignant phenotype 
is a current goal in cancer research and therapy. The core rationale of this approach 
is that uncontrolled malignant proliferation comes with a cost: a stressed phenotype 
comprising a risky balance between antagonistic metabolic and molecular signaling 
pathways controlling homeostasis and viability. Therefore, both, further induction and 
inhibition of stress response pathways can push cancer cells over an irreversible lethal 
threshold while sparing the normal cell counterparts. In this context, the results 
presented here highlight how mitogenic signaling can be manipulated to overload 
inherent stresses, disrupting the risky homeostatic robustness of cancer cells and 
sensitizing them to stress-targeted therapies.  
Many different mechanisms by which growth factors’ mitogenic signaling pathways 
contribute to the malignant progression have been emphasized in the cancer literature, 
and gain-of-function mutations along these mitogenic pathways are recognized driver 
oncogenic lesions in most human cancers. On the other hand, evidence is also 
accumulating showing that increasing mitogenic activation is not necessarily better for 
cancer cell fitness. For instance, EGFR and KRAS genes are frequently mutated in 
lung adenocarcinomas but with no overlap in individual samples.  Unni and co-workers 
have recently shown that synthetic lethality rather than redundancy underlies this 
mutual exclusivity (Unni et al., 2015). In melanomas, some BRAF V600E-driven 
tumors become resistant to the BRAF inhibitor vemurafenib through overexpression 
of BRAF V600E. In this context, withdrawal of the inhibitor resulted in tumor regression 
caused by a now over activated MAPK pathway (Thakur et al., 2013). These 
observations suggest that both inhibition and overactivation of canonically mitogenic 
pathways might disrupt tumor cell fitness. 
As for other growth factors, pro-tumor roles have been attributed to Fibroblast Growth 
Factor 2 signaling in different models and contexts (Reviewed by Turner & Grose, 
2010). However, most of these results are based on established cancer models, in 
which an optimal FGF2 signaling level was selected during malignant progression and 
is now part of its adapted and robust phenotype. Conversely, exogenous 
administration of FGF2 induced cytostatic or cytotoxic effects in breast cancer (Wang 
et al., 1998), Ewing’s sarcoma family tumor (Williamson et al., 2004), and 
medulloblastoma (Fogarty et al., 2007) cell models among others. Moreover, 
transgenic mice overexpressing FGF2 in all major organs developed into old age 
showing no increased tumorigenesis (Coffin et al., 1995). Furthermore, regular 
subcutaneous injections of FGF2 also decreased or prevented xenograft tumor growth 
in mice without noticeable toxicity (Sturla et al., 2000; Costa et al., 2008). These 
observations suggest that, while FGF2 signaling can be pathologically overridden in 
certain cancers, exogenous FGF2 administration can disrupt cancer cell homeostasis 
both in vivo and in vitro. 
Accordingly, our cell cycle kinetic analyses showed that FGF2 induces a general rather 
than phase-specific arrest in Y1 K-Ras-driven cancer cells. The observed delayed S-
phase entry and progression, G1 and G2 arrests incrementally contribute to FGF2 
cytostatic effects in these cells. This cell cycle abnormal progression led to increased 
average cell size and protein concentration implying that FGF2 signaling disrupts the 
homeostatic coupling between cell growth and proliferation in this model. It is known 
that EIF4E and S6K signaling play key roles in active protein synthesis and cell size 
control (Fingar et al., 2002). Thus, the resultant UPR activation is likely a consequence 
of the sustained EIF4E and S6K activity observed in FGF2-treated cells. One of the 
strategies of UPR to mitigate proteotoxic stress is to downregulate protein synthesis, 
helping to restore protein homeostasis (Ron & Walter, 2007). By eliciting active protein 
synthesis during an ongoing UPR, FGF2 might push proteotoxic stress over the 
viability threshold. Proteotoxic stress is recognized as a potential Achilles’ heel of 
malignant cells. Strikingly, treatment of multiple myeloma with bortezomib may result 
in a complete response. This high sensitivity can be attributed to the extensive 
production of immunoglobulins by multiple myeloma cells, which accumulates due to 
bortezomib proteasome inhibition leading to a fatal proteotoxic stress (Obeng et al., 
2006; Meister et al., 2007). This scenario provides a rationale for the observed 
induction of cell death triggered by the combination of FGF2 and bortezomib in these 
murine cancer cells. Noteworthily, FGF2 can also sensitize ESFT cells to bortezomib 
cytotoxicity. This panel of cancer cells was largely tolerant to 10 nM of bortezomib for 
48h. However, the results for A673, SK-N-MC, and TC-32 cells, in which FGF2 or 
bortezomib alone had minor effects on long-term cell viability but their association was 
highly toxic, highlight the therapeutic potential of this combination for inducing cancer 
cell death. It is promising because bortezomib can be very toxic to normal cells, limiting 
its therapeutic window (Chen et al., 2011). Additionally, K-Ras-depletion fully 
prevented the combined toxicity of FGF2 and bortezomib, linking the sensitizing effect 
of FGF2 to the malignant phenotype. Our results implicate that FGF2 signaling 
overactivation can efficiently disrupt proteostasis, resulting in a vulnerability common 
to cancer cells with diverse origins and driver oncogenic lesions. 
The risky balance between oncogenic activity and increased mobilization of the DDR, 
frequently found in cancer cells, represents the other vulnerability which we explored 
here to target these malignant cell models. FGF2 induced stalling or collapse of DNA 
replication forks in Y1 cells along S-phase. Similar replication stress has been shown 
to occur early in tumorigenesis; when the oncogenic activity causes increased firing of 
DNA replication origins leading to unscheduled S-phase progression (Hills & Diffley, 
2014). In this scenario, consequent DDR activation upregulating checkpoint proteins 
is an anti-cancer barrier that must be overcome in early malignant transformation 
(Bartkova et al., 2005; Gorgoulis et al., 2005). Y1 cells, like other malignant cells, 
displayed tonic levels of DDR activation which are compatible with high proliferation 
rates. It is noteworthy that FGF2 stimulation increased the activation of checkpoint 
proteins, reactivating this anti-cancer barrier and restraining cell proliferation in this K-
Ras-driven model. By enhancing replication stress on these cells, FGF2 also 
increased their dependence on checkpoint activity for survival; hence, the combination 
of FGF2 stimulation and checkpoint abrogation triggered cell death. Importantly, we 
showed that the same approach is also effective to trigger cell death in the panel of 
ESFT cells. The combination of FGF2 and VE-821, but not these agents alone, 
strongly reduced long-term viability of A673, SK-N-MC, and TC-32 cells. The 
increased dependency on DDR has been described in other cancer cells as an 
example of non-oncogene addiction (Luo et al., 2009). In this regard, checkpoint 
inhibition has recently been shown to sensitize cancer cells to radiotherapy and 
chemotherapy based on DNA damaging agents (Huntoon et al., 2013; Prevo et al., 
2012). However, both radiation and genotoxic agents are frequently very harmful also 
to non-malignant cells. We provided here evidence that mitogenic signaling activation 
and checkpoint inhibition might represent an efficient combination stress 
overloading/sensitization to exploit non-oncogene addiction in cancer therapies. 
The specific molecular mechanisms of FGF2 toxicity and sensitization to stress-
targeted inhibitors likely vary among Y1 and ESFT cells and engage different cell 
death subroutines as observed in our data. However, sustained overactivation of the 
Ras-MAPKs-ERK1/2 axis by FGF2 is a common feature of the vulnerabilities which 
we emphasized here. K-Ras depletion in Y1ΔK cells prevented MAPK-ERK1/2 
overactivation induced by FGF2. These cells showed no decrease in viability or 
proliferation rates in solid substrate, and no FGF2 toxicity or sensitization to 
proteasome or checkpoint inhibition. However, K-Ras depletion suppressed malignant 
traits of these cells. These data indicate that the tuning of K-Ras-MAPKs activation, 
which underlies the proliferation and malignancy in these cells, likely is also the 
molecular target of FGF2 toxicity. In ESFT cells, EWS/FLI-1 fusion protein suppresses 
Sprouty 1 expression, a negative-feedback regulator of Ras-MAPKs signaling 
downstream of FGF receptors; this genetic lesion was proposed to render 
unrestrained FGF2-induced proliferation in these cells in vitro and in vivo (Cidre-
Aranaz et al., 2017). Indeed, constitutive activation of MAPK-ERK1/2 was found in 
several ESFT cells, and a Ras dominant negative or MAPK-ERK1/2 pharmacological 
inhibition restrained the transforming activity of EWS/FLI-1 in immortalized fibroblasts 
(Silvany et al., 2000). Interestingly, FGF2 itself induces EWS/FLI-1 expression in 
ESFT cells (Girnita et al., 2000). Taken together, these data suggest that, at optimal 
growth conditions, exogenous FGF2 likely induce a positive feedback loop resulting in 
sustained and toxic MAPK-ERK1/2 overactivation in these cells. This scenario is 
supported by our data showing not only that FGF2 induced sustained higher levels of 
active ERK1/2, but also that MAPK inhibition, even 8h after FGF2 stimulus, restored 
cell homeostasis and rescued ESFT and Y1 cells from the synergic toxicities which 
we described above. 
The data and the background discussed here argue the question of whether, contra-
intuitively, growth factors signaling activation might be clinically explored in cancer 
therapies. Whilst this major question cannot be exhausted in the scope of this current 
work, the data provided here show that FGF2 can efficiently disturb the homeostasis 
of cancer cells from different origin and phenotypes, increasing the toxicity of 
checkpoint and proteasome inhibitors. Importantly, because we focused here on the 
sensitizing effect of FGF2, we used doses and times in which neither FGF2 nor the 
inhibitors trigger massive cell death as a single agent. This implies that the overall 
toxicity of these combinations over cancer cells can be further improved by tailoring 
the regimens.  
4.1- Conclusions 
Our data provide evidence that additional stimulation of the same signaling pathways 
overridden by the malignant transformation might further increase the mobilization and 
dependence on stress response pathways in cancer cells; hence, improving the 
efficacy and selectivity of stress-targeted therapies. This approach might be 
particularly useful at relapsed tumors resulting from acquired resistance to MAPK-
ERK1/2 inhibitors, but also provides a potential game-changing novel therapeutic 
perspective for other human cancers.  
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Figure S1. The tuning of MAPK-ERK1/2, but not p38 signaling underlies FGF2 
sensitization to ATR-checkpoint or proteasome inhibition in murine K-Ras-
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Figure 1. FGF2 impairs cell cycle progression in K-Ras-driven cancer cells. Serum-starved 
Y1D1 cells were stimulated by 10% serum with or without 10 ng/ml FGF2 to re-entry the cell 
cycle. Cells were subjected to a BrdU pulse 30 minutes before sample collection (every two 
hours). (A) Representative zebra plot flow cytometry data of BrdU-stained cells versus DNA 
content at the indicated times after stimulation comparing cell cycle re-entry and progression 
with or without FGF2. BrdU was added at 50 µM for 30 minutes before harvesting. The arrows 
indicate BrdU unlabeled S-phase cells. (B) Time-course flow cytometry analyses comparing the 
progression along cell cycle phases from 2h to 48h after stimulation by serum with or without 
FGF2. BrdU was added at 50 µM for 30 minutes before harvesting. (C) Quantifications of flow 
cytometry data showing phospho-histone H3 (S10) and DNA content double stain. The 
proportions of cells in each phase were measured 24, 28, 32, and 36h after stimulation with 
serum or serum + FGF2 in presence or absence of 2 µM colchicine. Mitotic cells were addressed 
by chromatin condensation indicated by phospho-histone H3 (S10) positive stain. Asterisks 
indicate significant differences. (***) means p ≤ 0.001. (One-way ANOVA of variance followed 




Figure 2. FGF2 reinforces replication stress in K-Ras-driven cancer cells increasing ATR-
checkpoint inhibition toxicity. A) Western blots comparing the levels of phospho-H2AX 
histone (γ-H2AX) in Y1 cells. Cells were serum starved and then re-stimulated with 10% serum 
(+S) or 10% serum + 10 ng/ml FGF2 (+S+F) for the indicated times. HPRT was used as a 
loading control. Quantifications were performed using Uvitec Alliance 9.7 
software. B) Representative immunofluorescence detection of single-stranded DNA (ssDNA) 
foci under native conditions. 50 mM of BrdU was incorporated to Y1 cells for 48h and then 
washed out. Cells were grown for additional 24h in complete media with or without 10ng/ml 
FGF2, and then stained for BrdU (green) and DNA (blue) under non-denaturing conditions. 
White bars correspond to 10 μm. C) Quantification of ssDNA foci per cell from the experiments 
described in B. Error bars indicate mean ± S.D. This assay was performed in triplicate with 
measurement of at least 65 cells per replicate (n = 65/assay). Asterisks indicate statistically 
significant differences. (***) means p ≤ 0.001. (Paired Student’s t-test) D) Representative 
histogram flow cytometry data comparing serum and serum + FGF2 stimulation regarding γ-
H2AX distribution along the cell cycle phases. Y1 cells were serum starved and then re-
stimulated by 10% serum with or without 10 ng/ml FGF2 for the indicated times. E) Western 
blots comparing the levels of the DDR and checkpoint markers phosphorylated Chk1 (p-Chk1), 
phosphorylated Chk2 (p-Chk2), phosphorylated p38 MAPK (p-p38), and p21 in Y1 cells re-
stimulated by 10% serum (+S) or 10% serum + 10ng/ml FGF2 (+S+F) for the indicated times 
after serum starvation. Total Chk1, p38, and HPRT were used as loading 
controls. F) Representative zebra plot flow cytometry data of Y1 cells growing in complete media 
in presence or absence of 10 ng/ml FGF2 for 48h, with concomitant addition of 5 µM of the ATM 
inhibitor KU-55933 (KU) or the ATR inhibitor VE-821 (VE). Annexin V/propidium iodide (PI) 
double stain was used to address cell death. G) Quantification of the experiments described in 
F. Error bars indicate mean ± S.D. of live cells (n=3, from independent experiments). Asterisks 
indicate statistically significant differences. (***) means p ≤ 0.001. (One-way ANOVA of variance 
followed by multiple comparison post-test). (#) refers to significant differences from the FGF2-
treated sample. 
 
Figure 3. FGF2 disrupts the proteostasis and sensitizes K-Ras-driven cancer cells to 
bortezomib toxicity. (A) Representative contour plot flow cytometry data from samples of 
figure 1B comparing serum and serum + FGF2 stimulation regarding cell size (Forward Scatter) 
and internal complexity (Side Scatter) along the time. (B) Measurements of the average cell size 
and the amount of protein per cell comparing serum and serum + FGF2 stimulated cells. Y1 
cells were serum starved and then re-stimulated by the indicated times. Asterisks indicate 
significant differences. (***) means p ≤ 0.001. (One-way ANOVA of variance followed by multiple 
comparison post-test). (n=6, from independent experiments) (C) Western blots comparing the 
levels of the UPR markers IRE1α and Bip (left panel); and the phosphorylated forms of S6 
ribosomal protein (p-S6) and eukaryotic translational initiation factor 4E (p-EIF4E; right panel) 
among the different stimuli. Y1 cells were serum starved and then re-stimulated with 10% serum 
(+S); 10 ng/ml FGF2 (+F); or both (+S+F) for the indicated times. HPRT and α-tubulin were the 
used as loading controls. (D) Representative zebra plot flow cytometry data of Y1 cells growing 
in complete media in presence or absence of 10 ng/ml FGF2 for 96h, with the addition of 20 nM 
bortezomib (BTZ) in the last 72h. Annexin V/propidium iodide (PI) double stain was used to 
address cell death. (E) Quantification of the experiments described in D. Error bars indicate 
mean ± S.D. of live cells (n=3, from independent experiments). Asterisks indicate statistically 
significant differences. (***) means p ≤ 0.001. (One-way ANOVA of variance followed by multiple 
comparison post-test). (#) refers to significant differences from the FGF2-treated sample. 
 
Figure 4. K-Ras overexpression is required for FGF2 toxicity and sensitization to cell 
death induced by checkpoint or proteasome inhibition. (A) Western blots comparing the 
levels of K-Ras among Y1 parental, Y1-scb control, and Y1ΔK K-Ras depleted cells. Lysates 
were prepared from cells growing at complete media. HPRT was used as a loading control. (B) 
Representative clonogenic assays comparing the viability of Y1-scb and Y1 ΔK cells. For each 
cell line, 100 cells/cm2 were plated in complete media in presence or absence of 10 ng/ml FGF2, 
grown for 15 days, and then fixed/stained. Culture media and FGF2 were renewed every 2 or 3 
days. (C) Representative growth curves comparing the proliferation of Y1 parental, Y1-scb 
control, and Y1 ΔK K-Ras depleted cells. For each cell line, 3x104 cells were plated in complete 
media in presence or absence of 10 ng/ml FGF2 and grown for the indicated times. Culture 
media and FGF2 of the reminiscent plates were renewed at every harvest point. Error bars 
indicate mean ± S.D. of technical triplicates. Asterisks indicate significant differences from Y1 
control condition. (***) means p ≤ 0.001. (Two-way ANOVA of variance followed by multiple 
comparison post-test) (D) Non-adherent proliferation assay comparing Y1-scb and Y1 ΔK cells. 
For each cell line, 1x104 cells were plated on ultra-low attachment 96 wells plates in complete 
media. Relative cell viability/proliferation was addressed after 1 day, to set up a baseline, and 
after 10 days to measure proliferation using CellTiter 96 AQueous (Promega). At least 8 wells per 
cell were assayed at each time point.  Asterisks indicate significant differences. (***) means p ≤ 
0.001. (One-way ANOVA of variance followed by multiple comparison post-test). (E) Flow 
cytometry data of Y1-scb control, and Y1 ΔK K-Ras depleted cells growing in complete media 
in presence or absence of 10 ng/ml FGF2 for 48h, with concomitant addition of 5 µM VE-821 
(VE). (F) Flow cytometry data of Y1-scb control, and Y1 ΔK K-Ras depleted cells growing in 
complete media in presence or absence of 10 ng/ml FGF2 for 96h, with the addition of 20 nM 
bortezomib (BTZ) in the last 72h. For E and F, Annexin V/propidium iodide (PI) double stain was 
used to address cell death. Error bars indicate mean ± S.D. of live cells (n=3, from independent 
experiments). Asterisks indicate statistically significant differences. (**) means p < 0.01 and (***) 
p ≤ 0.001. (One-way ANOVA of variance followed by multiple comparison post-test). (#) refers 
to significant differences from the FGF2-treated sample. (G) Representative assays comparing 
the long-term viability of Y1-scb and Y1 ΔK cells treated with the combinations of FGF2 and VE-
821 or bortezomib. For each cell line, 2,5x105 cells were plated and treated as described in E 
and F. After the treatments, the stimuli were washed out, the plates were grown in complete 
media for additional 10 days, and then fixed/stained.   
 
Figure 5. FGF2 promotes MAPK-ERK1/2 sustained overactivation and lethally sensitizes 
human cancer cells to checkpoint and proteasome inhibition. (A) Flow cytometry data of 
ESFT cells growing in complete media in presence or absence of FGF2 for 72h, with 
concomitant addition of KU-55933 (+KU), VE-821 (+VE), both (+KU +VE), or addition of 
bortezomib (+BTZ) in the last 48h. Concentrations as following: A673 cells FGF2 20 ng/ml, KU 
5 µM, VE 5 µM, and BTZ 10 nM; 1x105 cells were plated. RD-ES cells FGF2 20 ng/ml, KU 5 
µM, VE 5 µM, and BTZ 10 nM; 2,5x105 cells were plated. SK-N-MC cells FGF2 1 ng/ml, KU 5 
µM, VE 2 µM, and BTZ 10 nM; 2.5x105 cells were plated.  TC-32 cells FGF2 5 ng/ml, KU 5 µM, 
VE 2 µM, and BTZ 10 nM; 1,5x105 cells were plated.  Annexin V/propidium iodide (PI) double 
stain was used to address cell death. Results are expressed in absolute numbers of cells per 
plate 72h after stimulation. Error bars indicate mean ± S.D. of live cells (n=3, from independent 
experiments). Asterisks indicate statistically significant differences. (*) means p < 0.05, (**) p < 
0.01 and (***) p ≤ 0.001. (One-way ANOVA of variance followed by multiple comparison post-
test). (#) refers to significant differences from FGF2-treated sample. (B) Representative assays 
comparing the long-term viability of A673, TC-32 and SK-N-MC cells treated with the 
combinations of FGF2 and VE-821 or bortezomib. Cells were plated and treated as described 
in A. After the treatments, the stimuli were washed out, the plates were grown in complete media 
for additional 10 days, and then fixed/stained.  (C) Western blots comparing the levels of 
phospho-ERK1/2 (p-ERK1/2) and the stress markers IRE1α, phosphorylated Chk1 (p-Chk1), 
phosphorylated p38 MAPK (p-p38), and p21 in A673, TC-32 and Y1 cells in the presence or 
absence of FGF2 and the MEK inhibitor selumetinib. FGF2 (+) (20 ng/ml for A673; 5 ng/ml for 
TC-32 and 10 ng/ml for Y1 cells) was added to cells growing at complete media and 5 µM 
selumetinib was added to the indicated plates (MEKi +) 8h after FGF2 addition. Plates were 
harvested 24h after FGF2 addition. Total ERK and HPRT were used as loading controls. (D) 
Western blots comparing the levels of phospho-ERK1/2 (p-ERK1/2) and K-Ras expression 
among Y1-scb and Y1ΔK cells in the presence or absence of FGF2. FGF2 (+) (10 ng/ml) was 
added to cells growing at complete media and plates were harvested 24h later. Total ERK and 
actin were used as loading controls. (E) Representative assays comparing the long-term viability 
of A673, TC-32, and Y1 cells treated with the combinations of FGF2 and VE-821 or bortezomib, 
with or without the addition of the MEK inhibitor selumetinib. Cells were plated and treated as 
described in A. 8h after FGF2 stimulation, 5 µM of selumetinib (MEKi +) was added to the 
indicated plates. 72h after FGF2 addition, the stimuli were washed out, the plates were grown 
in complete media for additional 10 days, and then fixed/stained. 
 
Figure S1. The tuning of MAPK-ERK1/2, but not p38 signaling underlies FGF2 
sensitization to ATR-checkpoint or proteasome inhibition in murine K-Ras-driven and 
ESFT cancer cells. (A). Western blots comparing the levels of phospho-ERK1/2 (p-ERK1/2) in 
Y1, TC-32, and A673 cells in the presence or absence of FGF2 and MEK inhibitors. FGF2 (+) 
(20 ng/ml for A673; 5 ng/ml for TC-32 and 10 ng/ml for Y1 cells) was added to cells growing at 
complete media and 5 µM of selumetinib (Selu.), 500 nM of trametinib (Tram.), or 20 µM of 
U0126 were added to the indicated plates (MEKi +) 8h after FGF2 addition. Plates were 
harvested 24h after FGF2 addition. Total ERK and HPRT were used as loading controls. (B). 
Representative assays comparing the long-term viability of TC-32, SK-N-MC, A673, and Y1 
cells treated with the combinations of FGF2 and VE-821 or bortezomib, with or without the 
addition of MEK or p38 inhibitors. Cells were plated, let to adhere overnight and grown in 
complete media in presence or absence of FGF2 for 72h, with concomitant addition of VE-821 
(+VE), or addition of bortezomib (+BTZ) in the last 48h. Concentrations as following: A673 cells 
FGF2 20 ng/ml, VE 5 µM, and BTZ 10 nM; 1x105 cells were plated. SK-N-MC cells FGF2 5 
ng/ml, VE 2 µM, and BTZ 10 nM; 2.5x105 cells were plated. TC-32 cells FGF2 5 ng/ml, VE 2 
µM, and BTZ 10 nM; 1,5x105 cells were plated; Y1 cells FGF2 10 ng/ml, VE 5 µM, and BTZ 20 
nM; 2.5x105 cells were plated. 20 µM of the p38 inhibitor SB 202190 was added to the indicated 
plates at the time of stimulation. 8h after FGF2 stimulation, 500 nM of trametinib or 20 µM of 
U0126 were also added to the indicated plates. 72h after FGF2 addition, the stimuli were 
washed out, the plates were grown in complete media for additional 10 days, and then 
fixed/stained. 
 
 
